Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Debiopharm S.A.
PDS is getting rights to Merck's M9241, a tumor-targeting interleukin-12 fusion compound which is a key component, together with its own investigational HPV16-targeted immunotherapy, in a triple combination being studied to treat advanced HPV-positive cancers.
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.
Full-Life’s acquisition of Focus-X came after two other Chinese biotechs leaped into the fray for a leading position in China’s nascent radionuclide therapy market.
The German group says that 50% of future new launches are expected to come from externally sourced assets to take the strain of its organic discovery engine.
- Drug Delivery
- Other Names / Subsidiaries
- H3 Pharma
- Affinium Pharmaceuticals, Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.